217 related articles for article (PubMed ID: 24763373)
21. Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States.
Song DL; Altice FL; Copenhaver MM; Long EF
PLoS One; 2015; 10(2):e0116694. PubMed ID: 25658949
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India.
Venkatesh KK; Becker JE; Kumarasamy N; Nakamura YM; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP; Freedberg KA
PLoS One; 2013; 8(5):e64604. PubMed ID: 23741348
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.
Cipriano LE; Zaric GS; Holodniy M; Bendavid E; Owens DK; Brandeau ML
PLoS One; 2012; 7(9):e45176. PubMed ID: 23028828
[TBL] [Abstract][Full Text] [Related]
24. Routine HIV screening in France: clinical impact and cost-effectiveness.
Yazdanpanah Y; Sloan CE; Charlois-Ou C; Le Vu S; Semaille C; Costagliola D; Pillonel J; Poullié AI; Scemama O; Deuffic-Burban S; Losina E; Walensky RP; Freedberg KA; Paltiel AD
PLoS One; 2010 Oct; 5(10):e13132. PubMed ID: 20976112
[TBL] [Abstract][Full Text] [Related]
25. A mathematical model of biomedical interventions for HIV prevention among men who have sex with men in China.
Li J; Peng L; Gilmour S; Gu J; Ruan Y; Zou H; Hao C; Hao Y; Lau JT
BMC Infect Dis; 2018 Nov; 18(1):600. PubMed ID: 30486800
[TBL] [Abstract][Full Text] [Related]
26. Ending the HIV Epidemic Among Persons Who Inject Drugs: A Cost-Effectiveness Analysis in Six US Cities.
Krebs E; Zang X; Enns B; Min JE; Behrends CN; Del Rio C; Dombrowski JC; Feaster DJ; Gebo KA; Marshall BDL; Mehta SH; Metsch LR; Pandya A; Schackman BR; Strathdee SA; Nosyk B;
J Infect Dis; 2020 Sep; 222(Suppl 5):S301-S311. PubMed ID: 32877548
[TBL] [Abstract][Full Text] [Related]
27. Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive.
Gray RT; Watson J; Cogle AJ; Smith DE; Hoy JF; Bastian LA; Finlayson R; Drummond FM; Whittaker B; Law MG; Petoumenos K
Sex Health; 2018 Feb; 15(1):13-19. PubMed ID: 28874236
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
29. Reaching the 'first 90': Gaps in coverage of HIV testing among people living with HIV in 16 African countries.
Staveteig S; Croft TN; Kampa KT; Head SK
PLoS One; 2017; 12(10):e0186316. PubMed ID: 29023510
[TBL] [Abstract][Full Text] [Related]
30. Cost implications of HIV retesting for verification in Africa.
Lasry A; Kalou MB; Young PR; Rurangirwa J; Parekh B; Behel S
PLoS One; 2019; 14(7):e0218936. PubMed ID: 31260467
[TBL] [Abstract][Full Text] [Related]
31. Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings.
Ishikawa N; Dalal S; Johnson C; Hogan DR; Shimbo T; Shaffer N; Pendse RN; Lo YR; Ghidinelli MN; Baggaley R
J Int AIDS Soc; 2016; 19(1):21212. PubMed ID: 27978939
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Community-based Human Immunodeficiency Virus Self-Testing in Blantyre, Malawi.
Maheswaran H; Clarke A; MacPherson P; Kumwenda F; Lalloo DG; Corbett EL; Petrou S
Clin Infect Dis; 2018 Apr; 66(8):1211-1221. PubMed ID: 29136117
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of screening high-risk HIV-positive men who have sex with men (MSM) and HIV-positive women for anal cancer.
Czoski-Murray C; Karnon J; Jones R; Smith K; Kinghorn G
Health Technol Assess; 2010 Nov; 14(53):iii-iv, ix-x, 1-101. PubMed ID: 21083999
[TBL] [Abstract][Full Text] [Related]
35. Latent Tuberculosis Infection Testing Strategies for HIV-Positive Individuals in Hong Kong.
Wong NS; Chan KCW; Wong BCK; Leung CC; Chan WK; Lin AWC; Lui GCY; Mitchell KM; Lee SS
JAMA Netw Open; 2019 Sep; 2(9):e1910960. PubMed ID: 31490541
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
37. Implementation and Operational Research: A Cost-Effective, Clinically Actionable Strategy for Targeting HIV Preexposure Prophylaxis to High-Risk Men Who Have Sex With Men.
Ross EL; Cinti SK; Hutton DW
J Acquir Immune Defic Syndr; 2016 Jul; 72(3):e61-7. PubMed ID: 26977749
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
Alistar SS; Owens DK; Brandeau ML
PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
[TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
Long EF; Owens DK
Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
[TBL] [Abstract][Full Text] [Related]
40. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
